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ABSTRACT: This study describes a novel liposomal formula-
tion for siRNA delivery, based on the mixture of the neutral lipid
monoolein (MO) and cationic lipids of the dioctadecyldimethy-
lammonium (DODA) family. The cationic lipids dioctadecyldi-
methylammonium bromide (DODAB) and chloride (DODAC)
were compared in order to identify which one will most
eﬃciently induce gene silencing. MO has a ﬂuidizing eﬀect on
DODAC and DODAB liposomes, although it was more
homogeneously distributed in DODAC bilayers. All MO-based
liposomal formulations were able to eﬃciently encapsulate
siRNA. Stable lipoplexes of small size (100−160 nm) with a positive surface charge (>+45 mV) were formed. A more
uniform MO incorporation in DODAC:MO may explain an increase of the fusogenic potential of these liposomes. The siRNA-
lipoplexes were readily internalized by human nonsmall cell lung carcinoma (H1299) cells, in an energy dependent process.
DODAB:MO nanocarriers showed a higher internalization eﬃciency in comparison to DODAC:MO lipoplexes, and were also
more eﬃcient in promoting gene silencing. MO had a similar gene silencing ability as the commonly used helper lipid 1,2-dioleyl-
3-phosphatidylethanolamine (DOPE), but with much lower cytotoxicity. Taking in consideration all the results presented,
DODAB:MO liposomes are the most promising tested formulation for systemic siRNA delivery.
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1. INTRODUCTION
The ﬁrst ﬁndings regarding the RNA interference (RNAi)
mechanism1,2 opened a window of unique opportunities for
scientists in the ﬁeld of drug delivery. But even today, more
than 10 years since RNAi technology was introduced, the
success of siRNA therapy still depends on ﬁnding the best way
to eﬃciently deliver siRNA to the target cells.3−6
The use of nanocarriers composed of lipid molecules has
been one of the most explored alternatives to viral carriers for
the delivery of nucleic acids to cells.4,5,7 Felgner et al.
introduced cationic lipids as nucleic acid carriers in 1987,8
and since his pioneering work several liposomal formulations
were developed for plasmid DNA (pDNA) delivery.9,10 The
knowledge gained with pDNA gene delivery has been used to
develop rational approaches for the production of suitable
liposomal siRNA delivery systems. The success of the siRNA
strategy is dependent on several factors such as nanocarriers’
size, liposomal membrane ﬂuidity, surface charge, stability, and
ability to mediate eﬃcient encapsulation of the nucleic acids.
Reduced cytotoxicity, enhanced interaction, and internalization
by target cells, as well as biodegradability, are also desirable
characteristics for siRNA nanocarriers.
A helper lipid is often included in the liposomal formulation
to improve the system’s stability in physiologic conditions and/
or to facilitate structural changes to enhance endosomal
escape,11,12 which is one of the most important bottlenecks
in nucleic acid delivery.13 The neutral lipid 1,2-dioleyl-3-
phosphatidylethanolamine (DOPE) is typically introduced in
the formulations as a helper lipid, due to its propensity to adopt
nonlamellar structures. These structures are known to play a
role in membrane fusion and destabilization of endosomal
membranes, thereby allowing the release of the therapeutic
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cargo into the cytosol.12,14 In fact, the intracellular lamellar to
nonlamellar transition is thought to be a key factor governing
the eﬃciency of lipid-based transfection agents.14 It is believed
that the mechanism of nucleic acid release from lipoplexes
involves the neutralization of cationic lipids by the cellular
anionic lipids.15 This leads to an exchange of lipids between
lipoplexes and the negatively charged membranes of endo-
somes, most likely by fusion of the endosomal membranes with
the lipoplexes. The membrane destabilization process ﬁnally
results in the release of the nucleic acids into the cell cytoplasm.
Model membranes mimicking endosomal membranes have
been used to evaluate the fusogenic ability of nanocarriers
which gives an indication of the eﬃciency of nucleic acid release
into the cell cytoplasm.16−18 The relationship between
membrane fusion and lamellar to nonlamellar transition has
long been recognized as a key factor in the development of lipid
based nanocarriers.19 Not surprisingly, fusogenicity was found
to correlate with transfection eﬃciency as well.20
The positively charged component of the liposomal
formulations also has a strong impact on the transfection
eﬃciency of the nanocarriers.9,21,22 Liposomes formed by lipids
from the same family can exhibit diﬀerent characteristics, as
seen in the case of the dioctadecyldimethylammonium
(DODA) family.23−25 Although dioctadecyldimethylammo-
nium bromide (DODAB) and dioctadecyldimethylammonium
chloride (DODAC) only diﬀer in the nature of the counterion,
its eﬀect in the bilayer hydration signiﬁcantly inﬂuences several
properties like mean size and gel-to-liquid crystalline transition
temperature.23−25,34−36 Therefore, it can be expected that when
these lipids are mixed with other molecules, small diﬀerences
like the counterion will inﬂuence the overall properties of the
nanocarriers, and have a dramatic impact on the ﬁnal lipoplex
performance.18
Recent work from our group has introduced MO as a helper
lipid in liposomal formulations for pDNA delivery. Liposomes
prepared with DODAB and MO were able to complex pDNA
and eﬀectively transfect Human Embryonic Kidney 293T cells
without inducing signiﬁcant cytotoxicity.26,27 The evaluation of
the lipid organization in DODAB:MO mixtures showed the
existence of an inverted nonlamellar phase in excess MO, while
a lamellar organization prevails for MO fractions below 50%.28
The mechanism behind MO action is related not only to its
ability to ﬂuidize and stabilize the liposomal structures, but also
to the fact that it forms nonlamellar inverted cubic or hexagonal
phases, known to mediate the fusion processes.29 In eﬀect,
nonlamellar structures have already been reported to induce
fusion between nanoparticles and endosomal membranes, thus
enhancing the silencing eﬃciency of siRNA-nanoparticles.30
The aim of this work was to design a novel liposomal system
for siRNA delivery with good fusogenicity and little or no
cytotoxicity for therapeutic gene silencing. For that, we
evaluated MO as a helper lipid, as well as the importance of
the cationic lipid (DODAX, where X accounts for the Cl− or
Br− counterion) on the physicochemical characteristics,
cytotoxicity, cell uptake, and gene silencing eﬃciency of the
liposomal nanocarriers in vitro.
2. MATERIALS AND METHODS
2.1. Materials. The reagents dioctadecyldimethylammonium
bromide (DODAB), dioctadecyldimethylammonium chloride
(DODAC), 1-monooleoyl-rac-glycerol (MO), cholesterol (Chol),
bovine serum albumin (BSA), and dextran sulfate sodium salt were
supplied by Sigma-Aldrich (Bornem, Belgium). 1,2-Dioleoyl-sn-
glycero-3-phosphocholine (DOPC) was purchased from Corden
Pharma (Liestal, Switzerland) and 1,2-dioleyl-3-phosphatidylethanol-
amine (DOPE) was obtained from Lipoid GMBH (Ludwigshafen,
Germany). 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), 1,2-
dioleoyl-sn-glycero-3-phosphatidylethanolamine-7-nitrobenzofurazan
(NBD-PE) (λexc = 465 nm; λem = 535 nm), and 1,2-dioleoyl-sn-
glycero-phosphatidylethanolamine-N-(lissamine rhodamine B sulfon-
yl) ammonium salt (Rho-DOPE) (λexc = 545 nm; λem = 576 nm) were
purchased from Avanti Polar Lipids (Alabaster, AL, USA). RPMI-1640
and Opti-MEM cell culture mediums, L-Glutamine, fetal bovine serum
(FBS), Trypsin-EDTA solution, penicillin−streptomycin (5000 IU/
mL penicillin and 5000 μg/mL streptomycin), Geneticin, and
phosphate-buﬀered saline (PBS) were purchased from Gibco (UK).
LysoSensor Green was ordered from Molecular Probes (Merelbeke,
Belgium). Hoechst no 33342, Lipofectamine RNAiMax, and SYBR
Green were obtained from Invitrogen (Merelbeke, Belgium). Gel
Loading Solution (all-purpose, native agarose) was purchased from
Ambion, and MTT assay from Roche (Germany).
2.2. siRNA Duplexes. siRNA targeting the enhanced green
ﬂuorescent protein (siEGFP) and a universal negative control duplex
(siCONTROL) were purchased from Eurogentec (Seraing, Belgium).
siEGFP: sense strand = 5′-CAAGCUGACCCUGAAGUUCtt-3′;
antisense strand = 5′-GAACUUCAGGGUCAGCUUGtt-3′. siCON-
TROL: sense strand = 5′-UGCGCUACGAUCGACGAUGtt-3′;
antisense strand = 5′-CAUCGUCGAUCGUAGCGCAtt-3′. Lower
case letters represent 2′-deoxyribonucleotides. A Cy5-labeled siRNA
duplex (Eurogentec, Seraing, Belgium) was used for confocal
microscopy and uptake experiments. The lyophilized siRNAs were
dissolved in DEPC-treated water to a concentration of 20 μM,
aliquoted, and stored at −20 °C before use.
2.3. Preparation of Liposomes. Cationic liposomes composed of
DODAX:MO (molar ratio 2:1 and molar ratio 1:2) were prepared by
thin lipid ﬁlm hydration followed by extrusion. Brieﬂy, deﬁned
volumes of DODAC or DODAB and MO (20 mM stock solutions in
ethanol) were placed in a round-bottomed ﬂask and the solvent
evaporated under vacuum at 40 °C. The resultant lipid ﬁlm was
hydrated above the melting temperature of the cationic lipids (>50
°C) with 1 mL HEPES buﬀer, 25 mM pH 7.4, to a ﬁnal total lipid
concentration of 5 mM. Finally, the liposomes were extruded at room
temperature (RT) 11 times through a 100 nm pore sized
polycarbonate membrane (Whatman, USA) using the Avanti Polar
Lipids Mini-extruder.
2.4. Diﬀerential Scanning Calorimetry (DSC). DSC measure-
ments were performed on a VP-DSC (MicroCal, Northampton, MA)
calorimeter equipped with 0.542 mL twin cells for the reference and
sample solutions. The total lipid concentration was maintained at 1
mM for all measurements, which were performed at the scan rate of 1
°C/min and temperature range of 5−80 °C. The gel-to-liquid
crystalline transition temperature, Tm, was determined as the
temperature at the peak maximum. The enthalpy change associated
with each transition (ΔHm) was calculated from integration of the
thermograms using the equipment software (MicroCal Origin, v 7.0).
2.5. Lipid Mixing/Fusion Assay. Fluorescence resonance energy
transfer (FRET) was used to determine the fusogenic potential of
MO-based liposomes. FRET describes the energy transfer between
two ﬂuorophores (a donor (D) and a acceptor (A)), that is dependent
not only on the overlap of the emission spectrum of the donor and the
absorption spectrum of the acceptor, but also on the close localization
between both species.31 The energy transfer eﬃciency (ϕFRET)
between donor and acceptor can be an indication if lipid mixing/
fusion is occurring, because it implies the increase in the distance
between donor and acceptor, leading to the increase in the average of
the donor signal and in the signal loss of the acceptor ﬂuorophore, and
consequently decrease of ϕFRET. In this study, FRET between NBD-PE
(donor) and Rho-PE (acceptor)32 was used to monitor the process of
lipid mixing/fusion between MO-based liposomes and model
membrane liposomes (model endosomes). Model endosomes
composed of DOPC:DOPE:DOPS:cholesterol (5:1:1:2) (mol:mol)
were prepared by ethanolic injection as described elsewhere.26 The
donor/acceptor (DA) model endosomes were labeled with 2 mol % of
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NBD-PE and 1 mol % of Rho-PE, and the donor (D) model
endosomes were labeled with 2 mol % of NBD-PE. Model endosomes
were prepared at a ﬁnal concentration of 1 mM in MES-HEPES buﬀer,
20 mM, pH 7.2 or pH 5.5, to mimic early and late endosomes,
respectively. For the fusion assays, 50 μM of the DA or D model early
or late endosomes, and 50 μM of the MO-based liposomes were
mixed. HEPES-MES buﬀer pH 5.5 or 7.2 was added to the mixture to
make a ﬁnal volume of 2.5 mL. The ﬂuorescence emission spectra
(480−700 nm) was recorded in a Luminescence Spectrometer LS 50
(PerkinElmer) using a λexc = 460 nm, with spectral bandwidths of 1
nm. This wavelength corresponds to a point at which the spectra of
the two species, with equal stoichiometry, cross each other (isosbestic
point) such that the absorbance of the mixture of the two species at
this wavelength remains invariant. Therefore, at this speciﬁc excitation
wavelength, all the ﬂuorescence intensity changes are exclusively
dependent on energy transfer (FRET) (see Supporting Information,
Figure S1). ϕFRET was determined according to eq 1:
ϕ = − F
F
1FRET
DA
D (1)
where FDA is the (DA) endosome ﬂuorescence intensity (ﬂuorescence
of donor in the presence of acceptor), and FD is the (D) endosome
ﬂuorescence intensity (ﬂuorescence of the donor in the absence of the
acceptor), at λem = 530 nm.
ϕFRET was quantiﬁed as a function of time after addition of MO-
based liposomes to the (D) and (DA) model endosomes.
2.6. Preparation of siRNA-Lipoplexes. siRNA-lipoplexes were
prepared by incubating siRNA (diluted in HEPES buﬀer, 25 mM pH
7.4) with an equal volume of liposomes (in HEPES buﬀer, 25 mM pH
7.4) at the deﬁned lipid concentration to form each charge ratio (±).
Lipoplexes were incubated for 20 min at RT before use.
2.7. Gel Electrophoresis Assay. siRNA-lipoplexes were prepared
by mixing siCONTROL (2.5 μM) with the appropriate concentration
of liposomes to form siRNA-lipoplexes with DODAX:MO (2:1 and
1:2) at charge ratios (±) 5, 10, 15, and 20, as described in section 2.6.
siRNA (1.25 μM) and siRNA-lipoplexes were loaded onto a 1%
agarose gel TBE 1× using 1× loading dye. Electrophoresis was carried
out under a constant electric ﬁeld (100 V, 15 min) at RT and the gel
was stained with SYBR Green before visualization with a UV
Transilluminator 2000 (Bio Rad).
2.8. Dynamic Light Scattering (DLS) and Zeta (ζ) Potential.
Mean size, polydispersity index (PDI), and surface charge of liposomes
and siRNA-lipoplexes were determined by dynamic light scattering in a
Zetasizer Nano ZS (Malvern, UK), equipped with Dispersion
Technology Software (DTS). Measurements were made at 25 °C.
Samples were diluted to 1 mM with HEPES buﬀer 25 mM pH 7.4
before measurement and siRNA-lipoplexes were prepared with 200
nM siCONTROL. All results were based on intensity distributions.
2.9. Cell Lines and Culture Conditions. Human nonsmall cell
lung carcinoma wild type cells (H1299 wt) and H1299 cells stably
expressing enhanced green ﬂuorescent protein (H1299 eGFP) were
grown in RPMI 1640 cell culture medium supplemented with 1% L-
glutamine, 10% FBS, and 2% penicillin−streptomycin in a humidiﬁed
incubator (37 °C and 5% CO2). Cells were passed every 3 days using
0.05% Trypsin-EDTA solution in order to maintain subconﬂuency.
H1299 eGFP cells were treated with medium containing 1 mg/mL
Geneticin once per month for selection.
2.10. Cytotoxicity Assay. The percentage of H1299 eGFP viable
cells after incubation with siRNA-lipoplexes was determined by the
MTT assay. Brieﬂy, H1299 eGFP cells were seeded into 24-multiwell
plates (SPL Life Sciences, Korea) at a density of 35 × 103 cells per well
in complete cell culture medium. Immediately before siRNA-lipoplex
addition, the culture medium was removed and replaced by Opti-
MEM. 100 μL of siRNA-lipoplex solutions, prepared with 50 nM
siCONTROL, were added to each well and incubated for 4 h at 37 °C
and 5% CO2. Lipofectamine RNAiMax lipoplexes (50 nM
siCONTROL) were used as a control, and prepared in Opti-MEM
according to manufacturer’s instructions. After the 4 h incubation
period, siRNA-lipoplexes in the supernatant were removed, and the
medium was replaced by fresh cell culture medium. Cell viability was
assessed with the MTT assay after 48 h according to the
manufacturer’s instructions.
2.11. Cellular Uptake Assay. Cellular uptake of siRNA-lipoplexes
at 37 °C, 4 °C, and upon addition of sodium azide was quantiﬁed by
ﬂow cytometry. H1299 eGFP cells were seeded into 24-multiwell
plates at a density of 35 × 103 cells per well in complete cell culture
medium. Immediately before siRNA-lipoplex addition, the culture
medium was replaced by Opti-MEM. Cells were incubated with 100
μL siRNA-lipoplexes (ﬁnal concentration of 50 nM siRNA − 2% Cy5-
labeled siRNA and 98% siCONTROL) at 37 °C or at 4 °C. For the
control experiment at 4 °C, cells were preincubated 15 min on ice
before siRNA-lipoplexes were added. Lipofectamine RNAiMax
lipoplexes (50 nM siCONTROL, 2% Cy5-labeled siRNA) were
prepared in Opti-MEM, according to manufacturer’s instructions, and
used as a control. After 4 h incubation, the cells were washed with PBS
and a 0.1 mg/mL dextran sulfate solution was added for 5 min to
remove noninternalized siRNA-lipoplexes attached to the cell exterior.
Cells were further washed with PBS and detached with trypsin (0.25%
Trypsin-EDTA), which was then neutralized with 1 mL complete cell
culture medium. After centrifugation (1400 rpm, 7 min), the cell pellet
was resuspended in 300 μL ﬂow buﬀer (1% BSA and 0.1% sodium
azide in PBS) and kept on ice until analysis on a Beckman Coulter
Cytomics FC500 ﬂow cytometer equipped with an argon laser
(excitation of Cy5 at 633 nm). Uptake experiments were performed in
triplicate and 10 × 103 cells were considered for each sample. The
percentage of cellular internalization was determined as the percentage
of positive cells, deﬁned by a threshold set to have 0.5% of positive
cells on the control sample (cells not incubated with siRNA-
lipoplexes) at 37 °C. The same procedure was followed for the
treatment with sodium azide, after a 30 min preincubation period with
100 mM sodium azide.
2.12. EGFP Silencing. EGFP gene silencing was evaluated by ﬂow
cytometry. H1299 eGFP cells were seeded on 24-multiwell plates at a
density of 35 × 103 cells per well in complete cell culture medium.
siRNA-lipoplexes were prepared with siRNA negative control
(siCONTROL) or eGFP targeting siRNA (siEGFP) (10 nM or 50
nM siRNA) in HEPES buﬀer. Immediately before transfection, the
culture medium was removed and replaced by Opti-MEM. 100 μL
aliquots of siRNA-lipoplex solutions were added to each well, and after
4 h incubation at 37 °C and 5% CO2, noninternalized siRNA-
lipoplexes were removed and Opti-MEM replaced by fresh cell culture
medium. Lipofectamine RNAiMax lipoplexes (with siCONTROL and
siEGFP) were prepared in Opti-MEM, according to manufacturer’s
instructions, and used as control. Cells were prepared for analysis as
described for the cellular uptake assay, with excitation of eGFP at 488
nm. Transfections were performed in triplicate and 20 × 103 cells were
considered for each sample. The percentage of downregulation was
expressed according to eq 2:
= − ×⎜ ⎟⎛⎝
⎞
⎠%Downregulation 1
siEGFP
siCONTROL
100
(2)
where siEGFP and siCONTROL represent the mean EGFP
ﬂuorescence intensity of cells treated with siRNA-lipoplexes prepared
with siEGFP and siCONTROL, respectively.
2.13. Microscopy Studies. H1299 wild type cells were cultured
on glass bottomed 35 mm cell culture dishes (Greiner, Germany) at a
cell density of 1.25 × 105 cells per dish. Immediately before siRNA-
lipoplex addition, cell culture medium was replaced by Opti-MEM.
Cells were incubated with 100 μL siRNA-lipoplexes (ﬁnal concen-
tration of 50 nM siRNA − 50% Cy5-labeled siRNA and 50%
siCONTROL) at 37 °C. Lipofectamine RNAiMax lipoplexes were
prepared in Opti-MEM, and used as a control. After 4 h incubation,
cells were washed with PBS and a 0.1 mg/mL dextran sulfate solution
was added for 5 min to remove the noninternalized siRNA-lipoplexes.
Cells were washed with PBS and complete cell culture medium was
added. Samples were observed with a Nikon C1 confocal laser
scanning microscope (Nikon Belux, Brussels, Belgium) equipped with
a Plan Apo VC 60× 1.2 NA water immersion objective lens.
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Endolysosomal staining was made by 1 h incubation with LysoSensor
Green (1 μM), while 15 min incubation with Hoechst no 33342 (1
μM) was used for nucleus staining.
2.14. Statistical Analysis. Statistical analysis was performed with
GraphPad Prism 5.0 software, using the one-way ANOVA test,
followed by a Dunnett’s multiple comparison test. Results were
expressed as mean ± standard deviation (S.D.), and p < 0.05 was
considered to be statistically signiﬁcant.
3. RESULTS AND DISCUSSION
3.1. Physicochemical Characterization of DODAX:MO
Liposomes and siRNA-Lipoplexes. 3.1.1. Diﬀerential Scan-
ning Calorimetry (DSC) Assay. In this study we used
diﬀerential scanning calorimetry (DSC) to evaluate the eﬀect
of MO on the gel-to-liquid crystalline phase transition
temperature (Tm) and on the enthalpy change (ΔHm) of
DODAX:MO mixtures. Tm gives indications about the
liposomal membrane ﬂuidity and overall lipid organization,
which are extremely important characteristics for the success of
nucleic acid encapsulation and good transfection eﬃciency of
lipoplexes.33
Figure 1 shows the thermal behavior of DODAX:MO
mixtures at diﬀerent molar ratios. As can be seen in Figure 1A,
the peaks associated with the Tm became less well-deﬁned with
the increase of the amount of MO incorporated in DODAC
bilayers. Nevertheless, there is no clear shift of Tm to lower
temperatures, and Tm is still detected for the highest percentage
of MO tested (66% mol:mol). The presence of Tm indicates
that rigid bilayers are still present in all DODAC:MO
formulations.
As described before,23 DODAB presents a pretransition
temperature (Tp) due to the tilting of the DODAB chains prior
to the melting temperature. Figure 1B shows that the ﬁrst eﬀect
of MO incorporation was in the Tp of DODAB. With 25%
(mol:mol) MO (DODAB:MO (3:1)), Tp became broader and
less intense, and a further increase in MO (DODAB:MO (2:1))
completely abolished Tp. Nevertheless, in the formulation
DODAB:MO (1:1) (50% MO (mol:mol)), Tp appeared again,
which points to some phase separation between DODAB and
MO (Figure 1B).
Even though DODAC and DODAB lipids only diﬀer
chemically in the counterion, when dispersed in solution they
form vesicles with diﬀerent thermotropic behavior.23,24,34 The
fact that Cl− and Br− ions have diﬀerent sizes in solution
(average number of bound water molecules of 2.0 for Cl− and
1.5 for Br−35,36) indicates that the hydrated Cl− is larger than
the hydrated Br−. Therefore, Cl− ion cannot be as closely
associated with the cationic headgroup of the lipid as Br− ion,
making the neutralization of the positive charges of the cationic
headgroup less eﬀective with Cl− than with Br−. This results in
larger electrostatic repulsions between the head groups of
DODAC bilayers, not only within the aggregates, but also
between DODAC liposomes. Moreover, it was reported that,
for more hydrated counterions (as the case of Cl− in DODAC),
a dual behavior is observed: the presence of a less ordered polar
region due to strong repulsive interactions between the head
groups of the lipids, and stiﬀer hydrocarbon chains to avoid
contact of the hydrophobic region with the aqueous media.35
As a result, although DODAB forms bilayers more densely
packed at the headgroup region than DODAC,25,36 DODAC
vesicles exhibit higher Tm values and smaller sizes than DODAB
vesicles. Tm is related, in a complex way, to the energy required
to dehydrate the polar headgroup together with the associated
counterions, which in turn depends on the interaction of the
counterions with the surrounding aqueous media.
Tables 1 and 2 show, in more detail, the Tm and ΔHm of the
neat cationic lipids and DODAX:MO (2:1 and 1:2) mixtures.
Figure 1. Comparative eﬀects of MO on the DSC thermograms of
DODAC/B (1 mM) obtained in the heating mode, at scan rate 1 °C/
min. (A) DODAC:MO mixtures; (B) DODAB:MO mixtures.
Table 1. Gel-to-Liquid Crystalline Transition Temperature
(Tm) and Variation in Enthalpy (ΔHm) of DODAX:MO, as
Determined by DSC in the Heating Mode
DODAC:MO DODAB:MO
DODAC (2:1) (1:2) DODABa (2:1) (1:2)
Tm (°C) 48.6 48.3 46.7 44.4 47.1 46.5
ΔHm (kJ/mol) 41.5 29.2 8.8 47.4 25.4 11.6
ΔT1/2 (°C) 0.3 0.8 1.7 0.59 0.94 1.51
aNeat DODAB also presents a pretransition temperature Tp = 36.0
°C, ΔT1/2 = 1.10 °C with ΔHm = 33.5 kJ/mol.
Table 2. Gel-to-Liquid Crystalline Transition Temperature
(Tm) and Variation in Enthalpy (ΔHm) of DODAX:MO, as
Determined by DSC in the Cooling Mode
DODAC:MO DODAB:MO
DODAC (2:1) (1:2) DODABa (2:1) (1:2)
Tm (°C) 43.2 42.8 41.0 39.8 41.4 40.7
ΔHm (kJ/mol) 41.5 28.8 9.3 41.5 28.3 13.1
ΔT1/2 (°C) 0.8 1.0 1.2 0.42 0.98 0.98
aNeat DODAB also presents a pretransition temperature Tp = 10.0
°C, ΔT1/2 = 10.1 °C with ΔHm = 17.7 kJ/mol.
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The heating and cooling DSC results are in agreement with the
literature,23,24,28,34 with neat DODAC vesicles exhibiting higher
Tm than neat DODAB (48.6 and 44.4 °C in the heating and
43.2 and 39.8 °C in the cooling, respectively).
The inclusion of MO had a diﬀerent eﬀect on the two types
of liposomes: the presence of MO decreased the Tm for
DODAC liposomes, while in the case of DODAB formulations
this eﬀect was dependent on the MO concentration. In the
presence of 33% MO (mol:mol) the Tm of DODAB liposomes
increased from 44.4 to 47.1 °C, but the addition of 66% MO
(mol:mol) resulted in a decrease to 46.5 °C (Table 1). Even so,
the Tm is higher for DODAC in comparison to DODAB
vesicles. The same trend was observed in the cooling mode
(Table 2).
The increase in Tm of DODAB:MO (2:1) and (1:2) may be
related to the asymmetric distribution of MO in the bilayer,
leading to the formation of lipid domains rich in MO (more
ﬂuid) and rich in DODAB (more rigid). MO tends to abolish
the pretransition temperature Tp of DODAB, similar to what
has been observed with cholesterol at low concentrations.37,38
The DSC results clearly indicate that DODAC and DODAB
systems behave diﬀerently in the presence of MO. The
comparison between the transition temperatures is complex
and should be made carefully. The initial shift on Tm and
disappearance of Tp observed for DODAB:MO (2:1) is also
described for other systems, namely, for the incorporation of
cholesterol into bilayer membranes.38 It was shown that with
50% cholesterol there was still evidence of the gel-to-liquid
crystalline transition. For the mixtures DODAX:MO, Tm could
be measured even with 66% MO (mol:mol), although a
decrease in the Tm value was observed for both formulations,
indicating that MO increases ﬂuidity of the lipid bilayers.
It is known that ΔHm gives an indication of the number of
molecules that contribute to the Tm value. As can be seen in
Tables 1 and 2, the incorporation of MO also had an eﬀect on
ΔHm, even higher than on Tm. The decrease in ΔHm suggests
that fewer molecules contribute to the gel-to-liquid crystalline
transition when the MO content was increased. Nevertheless,
the eﬀects of MO were more pronounced for the DODAC:MO
mixtures. The decrease in ΔHm for DODAB:MO varying from
2:1 to 1:2 was 13.8 kJ/mol, while for DODAC:MO varying
from 2:1 to 1:2 was 20.4 kJ/mol (Table 1). This result suggests
that the incorporation of MO was more homogeneous in the
DODAC than in DODAB bilayers, which can be explained by
the fact that DODAC bilayers have less tight polar head groups,
where MO can be more easily incorporated and homoge-
neously distributed. On the other hand, DODAB polar head
groups are more tightly packed and hinder the integration of
MO within the DODAB bilayers. Altogether, these results
demonstrate that the helper lipid has the ability to ﬂuidize the
liposomal membranes, although to a diﬀerent extent. This fact
reinforces the idea that DODAB:MO and DODAC:MO
liposomes have a diﬀerent lipid structural organization.
3.1.2. Dynamic Light Scattering (DLS) Assay. The diﬀerent
formulations were fully characterized in terms of size and
surface charge, as demonstrated in Table 3.
DODAX:MO liposomes prepared by lipid ﬁlm hydration
followed by extrusion have a uniform size distribution (PDI <
0.2). The DODAB:MO liposomes have slightly higher mean
size than DODAC:MO liposomes, which is in accordance with
the literature.23,24 This diﬀerence in size is a consequence of the
diﬀerent counterions. Br− is less hydrated and has a smaller
headgroup area than Cl−, originating liposomes with lower
curvatures.25,36 The strong electrostatic repulsions that occur
between DODAC head groups increase the curvature of the
aggregates, originating liposomes with smaller sizes.35,36
The combination of 33% (mol:mol) or 66% (mol:mol) MO
with DODAC did not aﬀect the size of the DODAC-based
nanoparticles, although a reduction of more than 24% on the
Table 3. Physicochemical Characterization of DODAX:MO Liposomes and siRNA-Lipoplexesa
liposomes lipoplexes
mean size (nm) PDI ζ-potential (mV) mean size (nm) PDI ζ-potential (mV)
DODAC:MO (2:1) 101 ± 2 0.120 ± 0.016 55 ± 1 103 ± 1 0.089 ± 0.007 47 ± 1
DODAB:MO (2:1) 134 ± 3 0.156 ± 0.008 59 ± 1 158 ± 1 0.150 ± 0.017 54 ± 1
DODAC:MO (1:2) 104 ± 2 0.082 ± 0.006 57 ± 1 110 ± 1 0.068 ± 0.015 51 ± 1
DODAB:MO (1:2) 108 ± 3 0.061 ± 0.023 60 ± 2 120 ± 3 0.065 ± 0.017 52 ± 1
aZ-averaged mean size (nm), polydispersity index (PDI), and ζ-potential (mV) of liposomes and siRNA-lipoplexes (charge ratio (±) 15) with
siRNA ﬁnal concentration in lipoplexes of 200 nM. Data are presented as mean ± S.D.
Figure 2. Schematic representation of the proposed model for the structures of DODAX:MO siRNA-lipoplexes. Cryo-TEM images adapted from ref
28.
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mean size was observed from DODAB:MO (2:1) to
DODAB:MO (1:2) liposomes and lipoplexes.
A signiﬁcantly diﬀerent mean size was not observed for
nanocarriers with more MO (DODAX:MO (1:2)), probably
because MO is preferentially localized in the interior of the
lipidic structures, due to its natural negative curvature,39 making
the size of DODAX:MO (1:2) more similar and less
polydisperse.
Based on the DSC and DLS results (Figure 1, Tables 1, 2,
and 3), a model representing the structure of the DODAX:MO
siRNA-lipoplexes is suggested in Figure 2.
This hypothesis is based on the fact that, for DODAB-rich
formulations (DODAB:MO (2:1)), MO is distributed in the
lamellar phase of DODAB, forming MO-rich domains; and for
MO-rich formulations (DODAB:MO (1:2)), DODAB and MO
self-assemble, respectively, into lamellar and nonlamellar
phases.28 Therefore, for DODAX-enriched formulations
(DODAX:MO (2:1)), where lamellar liposomes are prevalent,
the encapsulation of siRNA will maintain the lamellar phase,
and a multilamellar structure will predominantly be formed,
with the anionic nucleic acids sandwiched between the lipid
membranes. For MO-enriched formulations (DODAX:MO
(1:2)), where a coexistence of lamellar and nonlamellar
aggregates was observed,28 the encapsulation of siRNA will
originate a DODAX lamellar phase enclosing the MO
nonlamellar phases, where the siRNA will preferentially localize.
Several biophysical studies30,40−42 also support two possible
models for the structure of lipoplexes, depending on the
percentage of helper lipid. Therefore, as represented in Figure 2,
distinct nanoscale structures of siRNA-lipoplexes might be
formed according to the DODAX:MO liposomes used to
encapsulate the siRNA.
Both MO-based liposomes, and siRNA-lipoplexes prepared
at charge ratio (±) 15, exhibited highly positive ζ-potentials: >
+55 mV and > +45 mV, respectively (Table 3). The presence of
a high concentration of MO (66% mol:mol) did not reduce the
surface charge of either liposomes or lipoplexes, reinforcing the
idea that MO is located preferably inside the nanostructures, as
previously observed for other MO enriched systems.28,43
Nanocarriers’ physicochemical properties largely govern the
success of every gene therapy strategy, and systemic
applications demand small nanocarriers, to prevent clogging
of capillaries, but also to allow them to extravasate through the
fenestrated endothelium.44,45 Size and surface charge also
determine colloidal stability and inﬂuence interaction with
cellular membranes and consequent cellular internalization.
The physicochemical characteristics of the produced siRNA-
lipoplexes were found to be promising for systemic delivery and
interaction with the cells.
3.1.3. siRNA Complexation Eﬃciency Assay. In spite of the
diﬀerences that MO induced on Tm and ΔHm of DODAC:MO
and DODAB:MO liposomes (Tables 1 and 2), all liposomal
formulations achieved good complexation eﬃciency at charge
ratio (±) 15 (Figure 3). Even though MO induced a diﬀerent
degree of ﬂuidity on the liposomes, it did not aﬀect their siRNA
complexation ability. The highly positive surface charge of the
liposomes was suﬃcient for an eﬀective siRNA complexation.
In subsequent experiments, lipoplexes prepared at charge
ratio (±) 15 were used, to ensure maximum siRNA loading.
3.2. Lipid Mixing Assay. Nanocarriers’ ability to destabilize
and fuse with membranes can be determinant for endosomal
escape and eﬃcient gene silencing.46 For the study of the
fusogenic ability of DODAX:MO liposomes, a FRET assay,
using the pair NBD-PE (donor) and Rho-PE (acceptor)
(Supporting Information, Figure S1), was performed to
evaluate the lipid mixing/fusion events between MO-based
liposomes and the model endosomes, at neutral and acidic
conditions.
FRET has been frequently used not only to detect lipid
mixing and fusion events, but also to study nucleic acid
complexation/destabilization processes.16−18,32,47 The ﬂuores-
cence intensities were used to calculate the energy transfer
eﬃciency (ϕFRET) (Supporting Information, Figure S2).
MO-based liposomes did not promote a markedly fusogenic
eﬀect compared to other systems,16,18 although a reduction in
FRET signal could still be detected at both pH 7.2 and pH 5.5
(Figure 4A and B). Surprisingly, the higher MO content in
DODAX:MO (1:2) did not provide higher fusogenic capacity
to liposomes. This result can be another indication that MO is
preferentially located inside of the lipidic structures, and is not
available to interact with the model endosomes to promote
fusion.
DODAC:MO formulations were able to fuse at higher extent
than DODAB:MO, likely a result of the more homogeneous
integration of MO in DODAC bilayers than in DODAB
bilayers (Figure 1 and Tables 1 and 2), supporting the MO
Figure 3. Gel electrophoresis of siRNA-lipoplexes prepared at charge ratios (±) 5, 10, 15, and 20, in HEPES buﬀer (25 mM, pH 7.4), with 1.25 μM
ﬁnal siRNA concentration.
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fusogenic potential. DODAX:MO (2:1) slightly decreased
ϕFRET over time, suggesting that the lipid mixing process
proceeds gradually over time. The acidiﬁcation of the
environment led to a small decrease on ϕFRET for DODAX:MO
(1:2) (Figure 4A compared to B), where MO was present at a
higher percentage.
Lipid mixing between positively and negatively charged
membranes is favored by electrostatic interactions. Therefore,
the occurrence of lipid interactions between MO-based
liposomes and negatively charged model endosomes, although
not to a great extent, were expected, and conﬁrmed in Figure 4.
As anticipated, diﬀerences in the fusogenic capacity were found
between DODAC and DODAB:MO liposomes, due to the
diﬀerent MO incorporation in the cationic bilayers.
3.3. Cytotoxicity, Transfection Eﬃciency, and Cellular
Internalization of DODAX:MO siRNA-Lipoplexes. An
MTT assay was used to evaluate the impact of siRNA-
lipoplexes on the metabolic activity of H1299 eGFP cells, 48 h
after incubation. In Figure 5A it is possible to observe the
cytotoxicity induced by Lipofectamine RNAiMax, DODAC:-
MO, and DODAB:MO lipoplexes at charge ratios (±) 10, 15,
and 20, prepared with 50 nM siRNA (maximum siRNA
concentration used for the gene silencing assays, in Figure 5B).
Figure 4. Ability of MO-based liposomes to destabilize model
endosomal membranes, as assessed by FRET assay. (A) ϕFRET after
incubation of MO-based endosomes with model early endosomes (pH
7.2). (B) ϕFRET after incubation of MO-based endosomes with model
late endosomes (pH 5.5). Controlmodel early or late endosomes in
the absence of MO-based liposomes, which corresponds to maximum
ϕFRET.
Figure 5. In vitro evaluation of siRNA-lipoplexes. (A) Metabolic
cytotoxicity induced by siRNA-lipoplexes on H1299 eGFP cells, as
determined by MTT assay, 48 h after incubation. (B) Evaluation of
eGFP silencing by siRNA-lipoplexes, 48 h after incubation, as
determined by ﬂow cytometry. (C and D) Cellular uptake of
siRNA-lipoplexes, after a 4 h incubation period with H1299 eGFP,
as determined by ﬂow cytometry. The percentage of cellular uptake
(C) and the mean ﬂuorescence intensity (D) are shown. L −
Lipofectamine RNAiMax. S.A. − Sodium Azide. MFI − Mean
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The commercial reagent Lipofectamine RNAiMax induced the
strongest cytotoxic response, while MO-based siRNA lipoplexes
were better tolerated by the cells. Interestingly, although having
very similar physicochemical characteristics (Figure 1 and
Tables 1 and 2), DODAB:MO lipoplexes were found to be less
cytotoxic than DODAC:MO lipoplexes, especially for higher
charge ratios. Besides the study of the cytotoxicity of the
lipoplexes, the highly charged liposomes used in these
formulations could be a matter of concern in terms of cellular
toxicity. Therefore, additional tests were performed to further
clarify the mechanism of cytotoxicity associated with the
DODAX:MO liposomes. The liposomal formulations with
higher percentage of cationic lipids (DODAX:MO (2:1)) were
chosen, and the eﬀect of the counterion was additionally
evaluated (Supporting Information, Figure S3). A similar
cytotoxic response was observed for DODAX:MO liposomes,
with DODAC:MO inducing higher metabolic cytotoxicity than
DODAB:MO liposomes. Nevertheless, it was also possible to
conclude that for the liposome concentrations used to form the
siRNA-lipoplexes, the cytotoxic eﬀect is not signiﬁcant, which is
thus related with the low cytotoxicity observed for the siRNA-
lipoplexes (Figure 5A).
Figure 5B reveals the silencing eﬃciency of MO-based
lipoplexes, as determined by the extent of eGFP down-
regulation in H1299 eGFP cells. When prepared with 10 nM
siRNA, DODAB:MO (2:1) and (1:2) lipoplexes led to higher
transfection eﬃciencies compared to DODAC:MO (2:1) and
(1:2). Of those formulations, DODAB:MO (2:1) was the most
eﬃcient in promoting eGFP silencing in H1299 eGFP cells
(61% downregulation), followed by DODAB:MO (1:2) (55%)
and DODAC:MO lipoplexes (<30%). There was a decrease in
the Lipofectamine RNAiMax silencing eﬃciency when the
concentration of siRNA was increased to 50 nM, as a
consequence of the high toxicity of this system (Figure 5A).
Therefore, with 50 nM siRNA, MO-based lipoplexes proved to
be more eﬃcient in the downregulation of eGFP than the
commercial reagent tested. Gene silencing was not increased
when higher charge ratios were used for transfection (data not
shown).
Figure 5C and D show the results obtained by ﬂow
cytometry when H1299 eGFP cells were incubated with
ﬂuorescently labeled siRNA-lipoplexes at 37 and 4 °C. In this
experiment, cells were also treated with sodium azide as
control. It is known that sodium azide inhibits oxidative
phosphorylation and thus energy-dependent uptake by
endocytosis. At 37 °C (Figure 5C), MO-based lipoplexes
were more eﬃciently internalized than Lipofectamine RNAi-
Max, while no signiﬁcant diﬀerences between the uptake of the
four MO-based lipoplexes could be detected. Incubation of the
cells at 4 °C or after sodium azide treatment almost completely
inhibited lipoplex uptake. This result indicates that energy-
dependent endocytosis is the primary route of cellular
internalization. Nevertheless, there may be a small contribution
by direct fusion with the plasma membrane for DODAB:MO,
judging from the results in Figure 5C. In any case this is a
minor eﬀect compared to Lipofectamine RNAiMax, as seen by
the percentage of positive cells (22%) after sodium azide
treatment (Figure 5C).
Although at a physiological temperature the percentage of
positive cells was high for all the MO-based lipoplexes (Figure
5C), the mean ﬂuorescence intensity observed (Figure 5D) was
quite diﬀerent. This indicates that the amount of internalized
lipoplexes per cell was higher for DODAX:MO (2:1) than for
DODAX:MO (1:2), though DODAB:MO lipoplexes were
more internalized than DODAC:MO lipoplexes (for both
DODAX:MO molar fractions).
It is well-known that an eﬃcient siRNA delivery depends on
several steps, including the encapsulation and protection of
siRNA, cellular internalization of the siRNA-lipoplexes, or
escape of the siRNA from the endosome into the cytoplasm.48
The nanocarrier structure can facilitate or hinder some of these
aspects, with consequences for the ﬁnal transfection eﬃciencies.
The counterions Cl− and Br− have important eﬀects on the self-
assembling structures of DODAC:MO and DODAB:MO:
DODAC:MO forms lamellar phases with less tight polar head
groups, where MO can be better distributed when compared to
DODAB bilayers; the more tightly packed head groups of
DODAB hinder MO integration into the bilayers, resulting in
the formation of MO-rich and DODAB-rich domains. There-
fore, the counterions will inﬂuence the performance of
DODAX:MO siRNA-lipoplexes at various levels. For instance,
the surrounding medium has probably a diﬀerent impact on
DODAB:MO and DODAC:MO lipoplexes, due to the diﬀerent
structural organization of the liposomes (Figure 1 and Tables 1
and 2), altering the siRNA-lipoplex stability and/or resulting in
uptake by distinct endocytic routes. In fact, DODAC:MO and
DODAB:MO siRNA-lipoplexes were found to have diﬀerent
stabilities when dispersed in serum, with DODAC:MO
lipoplexes releasing almost all of the siRNA content when in
contact with serum, while DODAB:MO lipoplexes released less
than 50% of the siRNA content (Supporting Information,
Figure S4). The experiment was performed by incubating
DODAX:MO (2:1) siRNA-lipoplexes with 50% (v:v) serum
(FBS), for 1 h at 37 °C, and the siRNA release determined by
ﬂuorescence ﬂuctuation spectroscopy (FFS) technique as
described before.49−52 The lower packed headgroup region of
DODAC:MO siRNA-lipoplexes is responsible for this higher
destabilization, because less stability is conferred to the siRNA
entrapped between lamellas. siRNA is then more easily
dissociated from the siRNA-lipoplexes by serum proteins.
Additionally, decreased stability can be reﬂected in a less
eﬃcient internalization of DODAC:MO siRNA-lipoplexes by
the cells, as observed in Figure 5D. Similar results have been
reported for other lipoplexes, where highly packed and dense
lamellar structures were found to be less destabilized by the
binding of serum proteins, and higher transfection eﬃciencies
were obtained.53
It is known that lipoplexes with a highly curved structure and
high ﬂuidity interact more readily with serum proteins. This fact
can lead to aggregation and/or disintegration, compared with
lipoplexes having stable lamellar structures.54,55 The phase and
ﬂuidity of the liposome bilayers are therefore important for the
nanoparticle’s stability and behavior when dispersed in complex
ﬂuids.
The siRNA-lipoplex cellular internalization can be inﬂuenced
by the counterion at another level. The reduced headgroup area
of DODAB, that leads to the formation of less curved
aggregates36 (conﬁrmed by the higher size of DODAB:MO
Figure 5. continued
Fluorescence Intensity. Results are expressed as mean ± SD. The
ANOVA statistical test was performed, followed by a Dunnett’s
multiple comparison test. *p < 0.05, **p < 0.01, and ***p < 0.005 for
10 nM siRNA. #p < 0.05, ##p < 0.01, and ###p < 0.005 for 50 nM
siRNA. The diﬀerences against Lipofectamine RNAiMax are indicated.
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compared to DODAC:MO formulations (Figure 3)), can
facilitate the adherence of the lipoplexes to the surfaces of the
cells.48 Another consequence of the diﬀerent structural
organization of DODAC and DODAB:MO liposomes is
observed on their fusogenic ability. The better incorporation
of MO within DODAC bilayers contributed to the better lipid
mixing between the model membranes and liposomal
membranes seen for DODAC-MO liposomes (Figure 4).
The poor performance of DODAC:MO lipoplexes can thus
be a consequence of the properties of the membrane bilayers,
and not solely due to lower internalization in comparison to
DODAB:MO lipoplexes (Figure 5D), since several steps of the
nanocarrier delivery process (siRNA-lipoplexes stability and
siRNA protection, cellular internalization, or fusogenic ability)
seem to be inﬂuenced by the presence of Cl− or Br.
Nevertheless, it has been shown that only a very limited
number of siRNA molecules are required at the cytoplasm to
induce a signiﬁcant gene silencing.56−58 This result was
observed for Lipofectamine RNAiMax, for which only a small
fraction of siRNA introduced into the cell cytoplasm was
suﬃcient to induce eGFP downregulation in almost 60% (50
nM siRNA), supporting it as a very eﬃcient siRNA carrier
system.59
The results for DODAB:MO liposomes give further support
to the fact that MO has important eﬀects on the properties of
liposomes and on the in vitro performance of the nanocarriers.
A similar number of positive cells for DODAB:MO (2:1) and
(1:2) nanoparticles (Figure 5C) was observed, but less siRNA
was internalized by cells treated with DODAB:MO (1:2)
lipoplexes (Figure 5D). Nevertheless, the same silencing
eﬃciency was observed for both formulations (Figure 5B).
This suggests that MO played a favorable role in the
Figure 6. Cellular uptake of siRNA-lipoplexes. Confocal images of the intracellular distribution of Cy5-labeled siRNA-lipoplexes after 4 h incubation
with H1299 wild-type cells. Scale bar 10 μm.
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transfection process, either by promoting a diﬀerent internal-
ization route for the two types of siRNA-lipoplexes, or by
determining an enhanced escape of siRNA from endosomes.
3.4. Confocal Laser Scanning Microscopy (CLSM).
Intracellular uptake of siRNA-lipoplexes by H1299 wild-type
cells was also visualized by CLSM (Figure 6). Fluorescent Cy5-
labeled siRNA (red) was used to track the lipoplexes; cell nuclei
were stained with Hoechst 33342 dye (blue) and endolysoso-
mal compartments with the LysoSensor Green dye.
Figure 6 shows that all four MO-based labeled lipoplexes
(DODAC:MO (2:1), DODAB:MO (2:1), DODAC:MO (1:2),
and DODAB:MO (1:2) siRNA-lipoplexes) were taken up by
the cells after 4 h incubation, even though at diﬀerent extents.
A clear diﬀerence in the internalization of DODAC:MO and
DODAB:MO lipoplexes was observed. DODAB:MO siRNA-
lipoplexes were internalized at a higher extent than
DODAC:MO lipoplexes, which corroborates the ﬂow cytom-
etry results. siRNA-lipoplexes are distributed throughout the
cytoplasm of the cells, but a conclusion about the co-
localization with endo/lysosomal compartments is not possible.
The uptake observed for Lipofectamine RNAiMax and MO-
based formulations was strikingly diﬀerent. A very low amount
of labeled siRNA lipoplexes is seen for Lipofectamine
RNAiMax compared to the other formulations. Once again
the diﬀerences observed are in agreement with the ﬂow
cytometry (Figure 5C and D).
3.5. Comparison of MO and DOPE as Helper Lipids.
MO-based siRNA-lipoplexes were compared with lipoplexes
prepared with the well-established helper lipid DOPE, in terms
of cytotoxicity, transfection eﬃciency, and internalization
(Figure 7). As the results presented so far indicate that
DODAB:MO liposomes are more promising for siRNA
delivery than DODAC:MO liposomes, comparison was made
with only DODAB:MO (2:1) liposomes.
No signiﬁcant diﬀerences were evident on the gene silencing
induced by DODAB:MO (2:1), DODAB:DOPE (2:1), and
neat DODAB lipoplexes (67%, 63%, and 73% eGFP down-
regulation, respectively, on Figure 7B). Nevertheless, DO-
DAB:MO (2:1) lipoplexes caused the lowest cytotoxicity in
H1299 eGFP cells (Figure 7A): 95% cell survival compared to
80% and 70% for DODAB:DOPE (2:1) and the DODAB
lipoplexes, respectively. Thus, MO was able to decrease the
toxicity without compromising the eﬃciency of lipofection.
Regarding the internalization, with DODAB:MO (2:1) and
neat DODAB, lipoplexes were taken up by 90% of the cells at
37 °C, while with DODAB:DOPE (2:1) only 50% of cells
internalized lipoplexes. The same trend was observed for the
mean ﬂuorescence intensity results. Sodium azide inhibits
oxidative phosphorylation and thus energy-dependent uptake
by endocytosis. The sodium azide uptake inhibition was more
eﬃcient for DODAB:DOPE (2:1) and neat DODAB
formulations than for DODAB:MO (2:1) lipoplexes.
The uptake of the DODAB:DOPE formulation was very low
compared to the other nanocarrier formulations, although the
transfection eﬃciency was not negatively aﬀected, which
suggests a very eﬃcient intracellular delivery mechanism for
this formulation as already observed for Lipofectamine
RNAiMax.
4. CONCLUSIONS
The work described here has important implications for the
design of siRNA-lipoplex delivery systems. The combination of
the nanocarriers’ components must be carefully optimized, as it
was clear that the liposomal structural organization and
membrane properties were highly dependent on the speciﬁc
Figure 7. Eﬀect of MO or DOPE on the cytotoxicity (A), transfection
eﬃciency (B), and cellular internalization (C and D) of siRNA-
lipoplexes. Lipoplexes were prepared with 10 nM siRNA for the
transfection experiment and with 50 nM siRNA for the toxicity and
uptake experiments. S.A. − Sodium Azide. MFI − Mean Fluorescence
Intensity. Results are expressed as mean ± SD. The ANOVA statistical
test was performed, followed by a Dunnett’s multiple comparison test.
*p < 0.05, **p < 0.01, and ***p < 0.005.
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mixture between the neutral lipid MO and the cationic lipid
DODAC or DODAB. A model for the structural organization
of DODAX:MO nanocarriers was proposed, showing a
diﬀerent lipid organization depending on the MO content.
Changing the counterion Cl− by Br− altered the nanocarriers’
properties in such a way that deﬁned the silencing eﬃciency.
The observed variations in structural properties of the four
tested formulations resulted not only in diﬀerent levels of
internalization, but also in diﬀerent transfection activities. The
uptake of the lipoplexes is predominantly occurring by an active
process, endocytosis being the main internalization route for
MO-based nanocarriers. Taking into consideration all the
results, we conclude that DODAB:MO liposomes were found
to be better siRNA-nanocarriers than DODAC:MO liposomes,
as they induce lower cytotoxicity, are better internalized, and
promote higher gene silencing in H1299 eGFP cells.
This work suggests a new formulation for siRNA delivery,
composed of the neutral lipid MO and the cationic lipid
DODAB, which is currently undergoing further optimization
for systemic siRNA delivery.
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